Risk Associated with Bilobectomy after Neoadjuvant Concurrent Chemoradiotherapy for Stage IIIA-N2 Non-small-cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Jong Ho | - |
dc.contributor.author | Kim, Jhingook | - |
dc.contributor.author | Kim, Kwhanmien | - |
dc.contributor.author | Shim, Young Mog | - |
dc.contributor.author | Kim, Hong Kwan | - |
dc.contributor.author | Choi, Yong Soo | - |
dc.date.accessioned | 2021-09-06T20:12:11Z | - |
dc.date.available | 2021-09-06T20:12:11Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-05 | - |
dc.identifier.issn | 0364-2313 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/108482 | - |
dc.description.abstract | Background The aim of the present study was to evaluate the outcomes of surgical resection, especially bilobectomy, after chemoradiation therapy to treat stage IIIA-N2 non-small-cell lung cancer. Methods Data from all patients who underwent surgical resection after neoadjuvant chemoradiation therapy for stage IIIA-N2 non-small-cell lung cancer between 1998 and 2007 were analyzed retrospectively. The chemotherapy regimen consisted of weekly paclitaxel plus cisplatin or weekly paclitaxel plus carboplatin for 5 weeks. The concurrent thoracic radiotherapy dose was 45 Gy over 5 weeks. Surgical resection was planned at around 4 weeks following the completion of neoadjuvant therapy. Results Of 186 patients who underwent neoadjuvant therapy, 23 bilobectomies, 28 pneumonectomies, and 135 lobectomies were performed. The early postoperative mortality rate (within 30 days after operation) was 7.1, 8.7, and 1.5% for the pneumonectomy, bilobectomy, and lobectomy groups, respectively. The late postoperative mortality rate (within 90 days) of the lobectomy, bilobectomy, and pneumonectomy groups was 5.9, 13, and 10.7%, respectively. Overall survival was significantly higher among patients treated by lobectomy than among those treated by bilobectomy (p = 0.041) or pneumonectomy (p = 0.010). Recurrence was significantly lower in patients treated by lobectomy than in those treated by pneumonectomy (p = 0.034). Conclusions Bilobectomy is associated with high operative mortality and poor long-term survival after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer. The outcomes of bilobectomy were similar to those of pneumonectomy in terms of overall survival, disease-free survival, and postoperative mortality. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject | PREOPERATIVE CHEMOTHERAPY | - |
dc.subject | PHASE-III | - |
dc.subject | BRONCHOGENIC-CARCINOMA | - |
dc.subject | SURGICAL RESECTION | - |
dc.subject | EARLY MORTALITY | - |
dc.subject | FOLLOW-UP | - |
dc.subject | THERAPY | - |
dc.subject | N2 | - |
dc.subject | RADIOTHERAPY | - |
dc.title | Risk Associated with Bilobectomy after Neoadjuvant Concurrent Chemoradiotherapy for Stage IIIA-N2 Non-small-cell Lung Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cho, Jong Ho | - |
dc.identifier.doi | 10.1007/s00268-012-1472-9 | - |
dc.identifier.scopusid | 2-s2.0-84863726907 | - |
dc.identifier.wosid | 000304096700038 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF SURGERY, v.36, no.5, pp.1199 - 1205 | - |
dc.relation.isPartOf | WORLD JOURNAL OF SURGERY | - |
dc.citation.title | WORLD JOURNAL OF SURGERY | - |
dc.citation.volume | 36 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1199 | - |
dc.citation.endPage | 1205 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | PREOPERATIVE CHEMOTHERAPY | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | BRONCHOGENIC-CARCINOMA | - |
dc.subject.keywordPlus | SURGICAL RESECTION | - |
dc.subject.keywordPlus | EARLY MORTALITY | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | N2 | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.